サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1577553

抗体薬物複合体（ADC）の世界市場

Antibody Drug Conjugates (ADC)

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
抗体薬物複合体（ADC）の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗体薬物複合体（ADC）の世界市場は2030年までに232億米ドルに達する見込み

2023年に94億米ドルと推定される抗体薬物複合体（ADC）の世界市場は、分析期間2023-2030年にCAGR 13.8%で成長し、2030年には232億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乳がんエンドユーズは、CAGR 14.5%を記録し、分析期間終了までに110億米ドルに達すると予測されます。血液がんエンドユーズ分野の成長率は、分析期間中CAGR 13.4%と推定されます。

米国市場は26億米ドルと推定、中国はCAGR18.5%で成長予測

米国の抗体薬物複合体（ADC）市場は2023年に26億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに52億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは18.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.3%と12.1%と予測されています。欧州では、ドイツがCAGR 11.0%で成長すると予測されています。

世界の抗体薬物複合体（ADC）市場- 主要動向と促進要因のまとめ

抗体薬物複合体とは何か、がん治療にどのような革命をもたらすのか？

抗体薬物複合体（ADC）は、がんを高い精度で標的化し治療するために設計されたバイオ医薬品の最先端クラスです。ADCは、モノクローナル抗体の標的化能力と強力な細胞傷害性薬剤を組み合わせ、健康な組織へのダメージを最小限に抑えながら、がん細胞に化学療法剤を直接送達することを可能にします。この標的化アプローチにより、ADCは腫瘍学、特に従来の治療に抵抗性が証明されたがんにおいて、ますます魅力的な選択肢となっています。がん細胞表面の特定のタンパク質に結合するモノクローナル抗体を利用することで、ADCは毒性ペイロードをより効率的に送達することができ、全身的な副作用を軽減しながら治療効果を高めることができます。ADCは、乳がん、リンパ腫、固形がんを含む様々ながんの治療に使用されています。

ADC市場はどのようにセグメンテーションされ、主要用途は何か？

技術的には、市場は使用されるリンカーとペイロードの種類に分けられ、これらは薬剤の安定性と有効性を確保する上で重要な要素です。用途別では、KadcylaやEnhertuのような治療の成功率が高いことから、現在乳がんがADC市場を独占しています。その他の標的適応症には血液悪性腫瘍や固形腫瘍があり、現在進行中の臨床試験はADCの使用をより多くのがん種に拡大することを目指しています。エンドユーザーには主に病院、腫瘍クリニック、がん研究機関が含まれ、ADCは包括的ながん治療レジメンの一部として投与されます。北米は高度な医療インフラとがん研究への高い投資により市場をリードしているが、欧州とアジア太平洋は医療費の増加とがん罹患率の増加により、主要地域として台頭してきています。

技術革新はADC市場にどのような影響を与えているか？

技術の進歩はADCの成長と有効性において極めて重要な役割を果たしています。リンカーケミストリーの革新はADCの安定性と精度を向上させ、がん部位での薬物放出を改善し、標的外毒性を低減しています。細胞毒性ペイロードの進歩もADCの効力を高め、薬剤耐性のがん細胞に対してより効果的になっています。さらに、新たながんバイオマーカーを同定する研究が進んでおり、ADCの潜在的な用途が現在の使用例以外にも拡大され、これまで治療不可能だったがんを標的とする次世代ADCの開発が可能になっています。FDAのような規制当局も、がん治療を一変させる可能性を認識し、新しいADC療法の承認を迅速化しています。

抗体薬物複合体市場の成長を促進する要因は何か？

抗体薬物複合体（ADC）市場の成長は、がんの有病率の増加や、より標的を絞った効果的な治療に対する需要など、いくつかの要因によって牽引されています。リンカー技術やペイロードデリバリーシステムの進歩により、ADCの有効性と安全性プロファイルが向上し、がん領域での採用拡大に寄与しています。さらに、遺伝子や分子マーカーに基づいて個々の患者に合わせた治療を行う個別化医療の台頭が、ADCの開発を後押ししています。主要なADC製品の臨床的成功と承認は、研究開発へのさらなる投資に拍車をかけ、将来のADC療法のパイプラインを拡大しています。さらに、従来の化学療法に比べて副作用の少ない治療法に対する認識と需要の高まりが、市場の成長をさらに後押ししています。

調査対象企業の例（注目の52社）

  • ADC Therapeutics SA
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co., Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • ImmunoGen, Inc.
  • MabPlex International

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24580

Global Antibody Drug Conjugates (ADC) Market to Reach US$23.2 Billion by 2030

The global market for Antibody Drug Conjugates (ADC) estimated at US$9.4 Billion in the year 2023, is expected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.8% over the analysis period 2023-2030. Breast Cancer End-Use, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Blood Cancer End-Use segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 18.5% CAGR

The Antibody Drug Conjugates (ADC) market in the U.S. is estimated at US$2.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 18.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.3% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global Antibody Drug Conjugates (ADC) Market - Key Trends and Drivers Summarized

What Are Antibody Drug Conjugates and How Are They Revolutionizing Cancer Treatment?

Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas, and solid tumors.

How Is the ADC Market Segmented and What Are the Key Applications?

Technologically, the market is divided into types of linkers and payloads used, which are critical components in ensuring the drug’s stability and efficacy. In terms of application, breast cancer currently dominates the ADC market, given the high success rate of treatments like Kadcyla and Enhertu. Other target indications include hematologic malignancies and solid tumors, with ongoing clinical trials aiming to expand the use of ADCs to more cancer types. End-users primarily include hospitals, oncology clinics, and cancer research institutes, where ADCs are administered as part of comprehensive cancer treatment regimens. North America leads the market due to its advanced healthcare infrastructure and high investment in oncology research, while Europe and Asia-Pacific are emerging as key regions due to increasing healthcare expenditures and cancer prevalence.

How Are Technological Innovations Impacting the ADC Market?

Technological advancements are playing a pivotal role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug release at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also enhancing the potency of ADCs, making them more effective against drug-resistant cancer cells. Moreover, ongoing research in identifying new cancer biomarkers is expanding the potential applications of ADCs beyond current use cases, allowing for the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies like the FDA are also expediting approvals for new ADC therapies, recognizing their potential to transform cancer treatment.

What Factors Are Driving the Growth in the Antibody Drug Conjugates Market?

The growth in the Antibody Drug Conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. The advancements in linker technologies and payload delivery systems have enhanced the efficacy and safety profile of ADCs, contributing to their growing adoption in oncology. Furthermore, the rise in personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is propelling the development of ADCs. Clinical success and the approval of leading ADC products have spurred further investment in R&D, expanding the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy are further driving market growth.

Select Competitors (Total 52 Featured) -

  • ADC Therapeutics SA
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co., Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • ImmunoGen, Inc.
  • MabPlex International

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Antibody Drug Conjugates (ADC) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cancer Drives Demand for Targeted Therapeutic Solutions
    • Technological Advancements in Biopharmaceuticals Propel Growth of ADC Market
    • Expansion of Precision Medicine Strengthens Business Case for Antibody Drug Conjugates
    • Rising Focus on Immuno-Oncology Fuels Innovation in ADC Development
    • Advancements in Targeted Drug Delivery Systems Propel Growth of ADC Therapies
    • Expanding Use of ADCs in Hematologic Malignancies Drives Market Demand
    • Rising Interest in Combination Therapies Strengthens Adoption of ADCs in Cancer Treatment
    • Increasing Focus on Personalized Medicine Expands Addressable Market for ADC-Based Therapies
    • Growing Awareness of Precision Therapeutics Sustains Demand for Targeted Cancer Therapies
    • Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
    • Rising Prevalence of Chronic Diseases Beyond Cancer Expands Applications of ADCs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Drug Conjugates (ADC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Breast Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Blood Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION